A study of ramantamig plus daratumumab versus investigator’s choice in participants with newly diagnosed multiple myeloma
| ISRCTN | ISRCTN15262649 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15262649 |
| ClinicalTrials.gov (NCT) | NCT07665450 |
| Clinical Trials Information System (CTIS) | 2026-526654-14 |
| Integrated Research Application System (IRAS) | 1014316 |
| Central Portfolio Management System (CPMS) | 73944 |
| Sponsor's protocol code number | 79635322MMY3004 |
| Sponsor | Janssen-Cilag International N.V. |
| Funder | Janssen Research and Development |
- Submission date
- 02/07/2026
- Registration date
- 24/08/2026
- Last edited
- 27/10/2026
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
Newly diagnosed multiple myeloma (NDMM) is a blood cancer that forms in a type of white blood cells (WBCs) called plasma cells. Although treatment options are available, but either cancer can come back, it can cause harmful side effects or spread to other parts of body. Hence, there is a need for better treatment options. JNJ-79635322 (Ramantamig) binds to proteins called B-cell maturation antigen* and G protein-coupled receptor family C Group 5 member D* found mainly on cancer cells, and cluster of differentiation 3 (CD3) found on T-cells. Upon binding, it activates T-cells and leads to killing of cancer cells. *Protein found on cancer cells that new treatments can target to help fight the disease.
Who can participate?
Participants aged 18 years or older with NDMM who are not suitable for or not planned to receive a stem cell transplant.
What does the study involve?
1.Screening phase (up to 28 days)
2.Treatment phase (Start of treatment until treatment completion or discontinuation): Participants will be randomly (by chance) assigned to either:
•Arm A: Ramantamig-D
•Arm B: Either DVRd or DRd (investigator's choice)
3.Follow-up phase: Until death, withdrawal of consent, lost to follow-up, or end of the trial, whichever occurs first.
Safety assessments include adverse events, physical examinations, vital signs, electrocardiogram, clinical laboratory tests, suicide assessments, and tuberculosis screening. The overall duration of the study will be approximately 5 years
What are the possible benefits and risks of participating?
There is no established benefit to participants of this study. Based on scientific theory, taking Ramantamig-D may improve NDMM. However, this cannot be guaranteed because Ramantamig-D is still under investigation as a treatment and it is not known whether Ramantamig -D will work.
Participants may experience some benefit from participation in the study that is not due to receiving study drug, but due to regular visits and assessments monitoring overall health. Participation may help other people with NDMM in the future.
Participants may have side effects from the drugs or procedures used in this study that may be mild to severe and even life-threatening, and they can vary from person to person. Potential risks include cytokine release syndrome (CRS; inflammation condition that may occur after treatment with some types of immunotherapy), immune effector cell-associated neurotoxicity syndrome (ICANS; neurological side effects may occur that include headaches or a condition of brain), infections, Hypogammaglobulinemia (low protein in blood that fights infection), immune-mediated toxicity (hyperactive immune system attacks healthy tissues), harm to mouth, skin and nails, systemic administration-related reaction (sARRs; side effects caused due to administration of drug into the vein), injection site reactions, tumor lysis syndrome (TLS; large numbers of cancer cells die rapidly releasing their contents in to the blood stream), cytopenias (abnormally low number of blood cells). There are other, less frequent risks. The participant information sheet and informed consent form, which will be signed by every participant agreeing to participate in the study, includes a detailed section outlining the known risks to participating in the study.
Not all possible side effects and risks related to Ramantamig-D are known at this moment. During the study, the sponsor may learn new information about Ramantamig-D. The study doctor will tell participants as soon as possible about any new information that might make them change their mind about being in the study, such as new risks.
To minimise the risk associated with taking part in the study, participants are frequently reviewed for any side effects and other medical events. Participants are educated to report any such events to their study doctor who will provide appropriate medical care. Any serious side effects that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team.
There are no costs to participants to be in the study. The sponsor will pay for the study drug and tests that are part of the study. The participant will receive reasonable reimbursement for study-related costs (e.g., travel/parking costs).
Where is the study run from?
Janssen-Cilag International NV (Netherlands)
When is the study starting and how long is it expected to run for?
September 2026 to February 2035
Who is funding the study?
Janssen Research and Development LLC (USA)
Who is the main contact?
medinfo@its.jnj.com
Contact information
Scientific, Public
Janssen Research & Development (Janssen-Cilag Ltd), 20 Grenfell Road
Maidenhead
SL6 1EH
United Kingdom
| Phone | +44 800 731 8450 / 10494 567 444 |
|---|---|
| medinfo@its.jnj.com |
Principal investigator
Kent and Canterbury Hospital, Ethelbert Road
Canterbury
CT1 3NG
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Open (masking not used) |
| Control | Active |
| Assignment | Parallel |
| Purpose | Safety |
| Scientific title | A phase 3 randomized study comparing ramantamig plus daratumumab versus investigator’s choice of daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) or daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma for whom hematopoietic stem cell transplant is not planned as initial therapy |
| Study acronym | TRIlogy-7 |
| Study objectives | Main objectives: To find out whether using ramantamig along with daratumumab can- help participants with NDMM live longer without the disease getting worse and- have no signs of cancer after 12 months of treatment, compared to standard treatment of DVRd or DRd in participants who are not suitable for or not planned to receive a stem cell transplant Secondary objectives: 1.To assess whether ramantamig-D can help patients with newly diagnosed multiple myeloma live longer (overall survival) compared to standard treatment of DVRd or DRd in participants who are not suitable for or not planned to receive a stem cell transplant 2.To find out whether ramantamig-D will improve 24-month sustained minimal residual disease (MRD) negative complete response rate. MRD is a situation where there are no detectable signs of remaining cancer cells for at least 24 months 3. To compare how well ramantamig-D works compared to standard treatments (DVRd or DRd) 4. To further understand how safe ramantamig-D is 5. To learn how participants feel and function during treatment, including their overall well-being (health-related quality of life), using participant questionnaires 6. To understand how well participants are able to tolerate (manage) treatment with ramantamig-D |
| Ethics approval(s) |
Approved 18/08/2026, North West – Haydock REC (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; haydock.rec@hra.nhs.uk), ref: 26/NW/0213 |
| Health condition(s) or problem(s) studied | Newly diagnosed multiple myeloma |
| Intervention | Experimental: Arm A: Ramantamig plus Daratumumab (Ramantamig-D) Participants will receive ramantamig D subcutaneous injection. Active Comparator: Arm B: Investigator's Choice (DVRd or DRd) Participants will receive either daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) or daratumumab, lenalidomide, dexamethasone (DRd) as per investigator's choice. Daratumumab will be administered subcutaneously. Lenalidomide will be administered orally. Bortezomib will be administered subcutaneously or intravenously. Dexamethasone will be administered orally or intravenously. |
| Intervention type | Drug |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Ramantamig, daratumumab, lenolidomide, bortezomib, dexamethosone |
| Primary outcome measure(s) |
Current primary outcome(s) as of 27/10/2026: |
| Key secondary outcome measure(s) |
Current key secondary outcome(s) as of 27/10/2026: |
| Completion date | 02/02/2035 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 120 Years |
| Sex | All |
| Target sample size at registration | 1000 |
| Key inclusion criteria | Current key inclusion criteria as of 27/10/2026: 1. Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria 2. Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: i. ineligible due to advanced age; or ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT 3. Have an eastern cooperative oncology status (ECOG) performance status of 0 to 2 4. Must sign an informed consent form (ICF) 5. Measurable disease at screening as assessed by central laboratory as defined in the protocol _____ Previous key inclusion criteria: 1. Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria 2. Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: i. ineligible due to advanced age; or ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT; or iii. deferral of high-dose chemotherapy with ASCT as initial treatment 3. Have an eastern cooperative oncology status (ECOG) performance status of 0 to 2 4. Must sign an informed consent form (ICF) 5. Measurable disease at screening as assessed by central laboratory as defined in the protocol |
| Key exclusion criteria | Current key exclusion criteria as of 27/10/2026: 1. Myeloma Frailty Score of greater than or equal to (>=) 2 with the exception of participants who have a score of 2 based on age alone 2. Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients 3. Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose of trial intervention or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial 4. Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM 5. Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids _____ Previous key exclusion criteria: 1. Myeloma Frailty Score of greater than or equal to (>=) 2 with the exception of participants who have a score of 2 based on age alone 2. Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients 3. Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial 4. Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM 5. Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids |
| Date of first enrolment | 23/09/2026 |
| Date of final enrolment | 15/08/2028 |
Locations
Countries of recruitment
- United Kingdom
- England
- Scotland
- Australia
- Brazil
- China
- Czech Republic
- France
- Germany
- Greece
- Israel
- Italy
- Japan
- Netherlands
- Poland
- Portugal
- Spain
- United States of America
Study participating centres
Canterbury
CT1 3NG
England
Blackpool
FY3 8NR
England
Heath Town
Wolverhampton
WV10 0QP
England
Cambridge
CB2 0QQ
England
Edinburgh
Lothian
EH4 2XU
Scotland
Bristol
BS2 8ED
England
London
NW1 2PG
England
Mindelsohn Way
Edgbaston
Birmingham
B15 2GW
England
Colchester
CO4 5JL
England
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan | The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu |
Editorial Notes
27/10/2026: The following changes were made to the study record:
1. The date of first enrolment was changed from 28/10/2026 to 23/09/2026.
2. The primary outcome(s) were changed.
3. The key secondary outcome(s) were changed.
4. The key inclusion criteria were changed.
5. The key exclusion criteria were changed.
6. Contact details updated.
25/09/2026: Internal review.
08/09/2026: Ethics approval details added. The date of first enrolment was changed from 13/09/2026 to 28/10/2026.
22/08/2026: ISRCTN received notification of combined HRA/MHRA approval for this trial on 22/08/2026.
02/07/2026: Trial's existence confirmed by NHS HRA.